immune system
• proportions of spleen NK cells expressing intracellular IFN-gamma from MCMV infected mice are increased
• there is 75% less actively proliferating NK cells in the spleen after MCMV infection compared to controls
• NK cells have less proliferation in response to IFN-alpha treatment compared to controls and thus do not have the 2- to 6-fold gains in liver NK cell numbers that wild-type controls do
|
• NK cells from MCMV-infected mice have about 3-fold less cytotoxicity than wild-type NK cells
• NK cells fail to increase their cytolytic activity when treated with recombinant IFN-alpha
|
• serum IFN-gamma levels are 6-fold higher than controls in mice infected with MCMV
|
• mice infected with LCMV have 5-fold higher levels of IL-12 p40 than in controls
|
endocrine/exocrine glands
• mice develop spontaneous mammary adenocarcinoma with a median tumor onset of 14.5 months
|
homeostasis/metabolism
• serum IFN-gamma levels are 6-fold higher than controls in mice infected with MCMV
|
• mice infected with LCMV have 5-fold higher levels of IL-12 p40 than in controls
|
integument
• mice develop spontaneous mammary adenocarcinoma with a median tumor onset of 14.5 months
|
hematopoietic system
• proportions of spleen NK cells expressing intracellular IFN-gamma from MCMV infected mice are increased
• there is 75% less actively proliferating NK cells in the spleen after MCMV infection compared to controls
• NK cells have less proliferation in response to IFN-alpha treatment compared to controls and thus do not have the 2- to 6-fold gains in liver NK cell numbers that wild-type controls do
|
• NK cells from MCMV-infected mice have about 3-fold less cytotoxicity than wild-type NK cells
• NK cells fail to increase their cytolytic activity when treated with recombinant IFN-alpha
|
neoplasm
• mice develop spontaneous mammary adenocarcinoma with a median tumor onset of 14.5 months
|